Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 19, 2010 - Issue 2
Submit an article Journal homepage
296
Views
33
CrossRef citations to date
0
Altmetric
Drug Evaluations

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

Michelle Head Waikato Hospital, Regional Cancer Centre, Waikato Hospital, Private Bag 3200, Hamilton 3240, New Zealand +64 7 839 8604; +64 7 839 8778; [email protected]
, MB ChB &
Michael B Jameson Waikato Hospital, Regional Cancer Centre, Waikato Hospital, Private Bag 3200, Hamilton 3240, New Zealand +64 7 839 8604; +64 7 839 8778; [email protected]
, FRACP FRCP(Edin) PhD
Pages 295-304 | Published online: 06 Jan 2010

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

M Roshni Ray, David Jablons & Biao He. (2010) Lung cancer therapeutics that target signaling pathways: an update. Expert Review of Respiratory Medicine 4:5, pages 631-645.
Read now

Articles from other publishers (32)

Yiming Zhang, Zhijun Ouyang, Mengsi Zhan, Rui Yang, Yue Gao, Lulu Li, Rui Guo, Xiangyang Shi & Xueyan Cao. (2023) An Intelligent Vascular Disrupting Dendritic Nanodevice Incorporating Copper Sulfide Nanoparticles for Immune Modulation‐Mediated Combination Tumor Therapy. Small.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2023. DiSaia and Creasman Clinical Gynecologic Oncology. DiSaia and Creasman Clinical Gynecologic Oncology 464 488.e11 .
Shubhmita Bhatnagar, Vishnu Revuri, Manan Shah, Peter Larson, Zekun Shao, Daohai Yu, Swayam Prabha, Thomas S. Griffith, David Ferguson & Jayanth Panyam. (2022) Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy. Cancers 14:24, pages 6091.
Crossref
Shizheng Tong, Wei Zhao, Duoyi Zhao, Weilin Zhang & Zhiyu Zhang. (2022) Biomaterials-Mediated Tumor Infarction Therapy. Frontiers in Bioengineering and Biotechnology 10.
Crossref
Duoyi Zhao, Xu Huang, Zhiyu Zhang, Jianxun Ding, Yan Cui & Xuesi Chen. (2021) Engineered nanomedicines for tumor vasculature blockade therapy. WIREs Nanomedicine and Nanobiotechnology 13:3.
Crossref
Umme Ayesa & Parkson Lee-Gau Chong. (2020) Polar Lipid Fraction E from Sulfolobus acidocaldarius and Dipalmitoylphosphatidylcholine Can Form Stable yet Thermo-Sensitive Tetraether/Diester Hybrid Archaeosomes with Controlled Release Capability. International Journal of Molecular Sciences 21:21, pages 8388.
Crossref
Stacey Cerón, Brian J. North, Sean A. Taylor & David A. Leib. (2019) The STING agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA) stimulates an antiviral state and protects mice against herpes simplex virus-induced neurological disease. Virology 529, pages 23-28.
Crossref
Carla Fernandes, Maria Carraro, João Ribeiro, Joana Araújo, Maria Tiritan & Madalena Pinto. (2019) Synthetic Chiral Derivatives of Xanthones: Biological Activities and Enantioselectivity Studies. Molecules 24:4, pages 791.
Crossref
João Ribeiro, Cláudia Veloso, Carla Fernandes, Maria Elizabeth Tiritan & Madalena M. M. Pinto. (2019) Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives. Molecules 24:1, pages 180.
Crossref
Amir Daei Farshchi Adli, Rana Jahanban-Esfahlan, Khaled Seidi, Sonia Samandari-Rad & Nosratollah Zarghami. (2018) An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chemical Biology & Drug Design 91:5, pages 996-1006.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2018. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology 470 492.e10 .
El Bairi Khalid, EL-Meghawry EL-Kenawy Ayman, Heshu Rahman, Guaadaoui Abdelkarim & Agnieszka Najda. (2016) Natural products against cancer angiogenesis. Tumor Biology 37:11, pages 14513-14536.
Crossref
Wantong Song, Zhaohui Tang, Dawei Zhang, Mingqiang Li, Jingkai Gu & Xuesi Chen. (2016) A cooperative polymeric platform for tumor-targeted drug delivery. Chemical Science 7:1, pages 728-736.
Crossref
Wantong Song, Zhaohui Tang, Dawei Zhang, Haiyang Yu & Xuesi Chen. (2015) Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions. Small 11:31, pages 3755-3761.
Crossref
Thomas F. Gajewski & Leticia Corrales. (2015) New perspectives on type I IFNs in cancer. Cytokine & Growth Factor Reviews 26:2, pages 175-178.
Crossref
Charlene M. Downey, Mehrnoosh Aghaei, Reto A. Schwendener & Frank R. Jirik. (2014) DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization. PLoS ONE 9:6, pages e99988.
Crossref
Shi-Jie Zhang, Zhi-Shan Ding, Fu-Sheng Jiang, Qiu-Fu Ge, Dian-Wu Guo, Hai-Bo Li & Wei-Xiao Hu. (2014) Synthesis, anticancer evaluation and docking study of vadimezan derivatives with carboxyl substitution. Med. Chem. Commun. 5:4, pages 512-520.
Crossref
Kewal K. JainKewal K. Jain. 2014. Applications of Biotechnology in Oncology. Applications of Biotechnology in Oncology 617 669 .
Joseph Conlon, Dara L. Burdette, Shruti Sharma, Numana Bhat, Mikayla Thompson, Zhaozhao Jiang, Vijay A. K. Rathinam, Brian Monks, Tengchuan Jin, T. Sam Xiao, Stefanie N. Vogel, Russell E. Vance & Katherine A. Fitzgerald. (2013) Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid. The Journal of Immunology 190:10, pages 5216-5225.
Crossref
Athanasios G. Pallis & Konstantinos N. Syrigos. (2013) Targeting tumor neovasculature in non-small-cell lung cancer. Critical Reviews in Oncology/Hematology 86:2, pages 130-142.
Crossref
Murielle Mimeault & Surinder K. Batra. (2013) Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discovery Today 18:3-4, pages 128-140.
Crossref
David E. Goertz, Margarita Todorova, Omid Mortazavi, Vlad Agache, Branson Chen, Raffi Karshafian & Kullervo Hynynen. (2012) Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles. PLoS ONE 7:12, pages e52307.
Crossref
Sujeong Kim, Leonid Peshkin & Timothy J. Mitchison. (2012) Vascular Disrupting Agent Drug Classes Differ in Effects on the Cytoskeleton. PLoS ONE 7:7, pages e40177.
Crossref
M. O. Leach, B. Morgan, P. S. Tofts, D. L. Buckley, W. Huang, M. A. Horsfield, T. L. Chenevert, D. J. Collins, A. Jackson, D. Lomas, B. Whitcher, L. Clarke, R. Plummer, I. Judson, R. Jones, R. Alonzi, T. Brunner, D. M. Koh, P. Murphy, J. C. Waterton, G. Parker, M. J. Graves, T. W. J. Scheenen, T. W. Redpath, M. Orton, G. Karczmar, H. Huisman, J. Barentsz & A. Padhani. (2012) Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. European Radiology 22:7, pages 1451-1464.
Crossref
Shannon N. Westin, Anil K. Sood & Robert L. Coleman. 2012. Clinical Gynecologic Oncology. Clinical Gynecologic Oncology 539 560.e6 .
Patricia M. LoRusso, Scott A. Boerner & Sally Hunsberger. (2011) Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?. Journal of Clinical Oncology 29:22, pages 2952-2955.
Crossref
Qi ZengShiwen PengArchana MonieMing YangXiaowu PangChien-Fu HungT.-C. Wu. (2011) Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents. Human Gene Therapy 22:7, pages 809-819.
Crossref
Wenkui Li, Hui Lin, Harold T. Smith & Francis L.S. Tse. (2011) Developing a robust ultrafiltration-LC–MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma. Journal of Chromatography B 879:21, pages 1927-1933.
Crossref
Xuexin He, Su Li, He Huang, Zhiming Li, Likun Chen, Sheng Ye, Jiajia Huang, Jing Zhan & Tongyu Lin. (2011) A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. British Journal of Clinical Pharmacology 71:6, pages 860-870.
Crossref
A Palumbo, F Hauler, P Dziunycz, K Schwager, A Soltermann, F Pretto, C Alonso, G F Hofbauer, R W Boyle & D Neri. (2011) A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. British Journal of Cancer 104:7, pages 1106-1115.
Crossref
Kari Ann Shirey, Quan M Nhu, Kevin C Yim, Zachary J Roberts, John R Teijaro, Donna L Farber, Jorge C Blanco & Stefanie N Vogel. (2011) The anti-tumor agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), induces IFN-β-mediated antiviral activity in vitro and in vivo. Journal of Leukocyte Biology 89:3, pages 351-357.
Crossref
Shi-Jie Zhang & Wei-Xiao Hu. (2010) Vadimezan: 2-(5,6-dimethyl-9-oxo-9 H -xanthen-4-yl)acetic acid . Acta Crystallographica Section E Structure Reports Online 66:8, pages o2082-o2083.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.